News
Novel liver dialysis device may safely curb ACLF
- Author:
- Neil Osterweil
The investigational DIALIVE liver dialysis system removes and replaces albumin and filters endotoxins in patients with acute-on-chronic liver...
News
Worse survival with recurrent AIH after transplant
- Author:
- Neil Osterweil
Patients with recurrent autoimmune hepatitis after transplant have a more than 10-fold greater risk for graft failure than those without...
News
Real-world CAR T outcomes for DLBCL mimic clinical trials
- Author:
- Neil Osterweil
Survival and safety outcomes in the monde réel (real world) were comparable with those seen in clinical trials for patients with advanced...
News
Ponatinib/blinatumomab start strong against Ph+ALL
- Author:
- Neil Osterweil
The combined agents were associated with high complete response and molecular remission rates as frontline...
News
HMAs benefit children with relapsed/refractory AML
- Author:
- Neil Osterweil
Azacitidine and decitabine alone or in combination may help children and young adults reach stem cell transplant...
News
Novel molecule prolongs half-life of bleeding disorder treatments
- Author:
- Neil Osterweil
In a perfect example of serendipity, an aptamer designed to prevent ischemic strokes actually results in...
News
CAR T cells rescue younger children with relapsed/refractory ALL
- Author:
- Neil Osterweil
Children younger than 3 years with relapsed/refractory acute lymphoblastic leukemia had CAR T therapy outcomes similar to those of older children...
News
Experimental antibody-drug conjugate shown active against r/r DLBCL
- Author:
- Neil Osterweil
The experimental antibody-drug conjugate naratuximab targets CD37, a surface marker on most B-cell lymphoma...
News
Promising HER2+/HR– breast cancer survival with de-escalated therapy
- Author:
- Neil Osterweil
Dual HER2 blockade and paclitaxel therapy was associated with excellent overall and invasive disease-free...
News
GLOW: Ibrutinib+venetoclax shines in first line for CLL/SLL
- Author:
- Neil Osterweil
Fixed-duration therapy with the combo was associated with high progression-free survival and undetectable...
News
CRC screening guidelines: 45 is the new 50, and 85 is the new 75
- Author:
- Neil Osterweil
Multiple guidelines, levels of evidence, different screening methods with varying efficacy, individual risk factors - how can clinicians make...
News
CONCERT: Better QoL but not survival with cabazitaxel in metastatic HER2– breast cancer
- Author:
- Neil Osterweil
Sensory peripheral neuropathy was significantly less frequent with cabazitaxel every 3 weeks than with weekly...
News
Genomic signature predicts safety of omitting RT in early breast cancer
- Author:
- Neil Osterweil
Patients categorized as low risk who did not undergo radiation had a 10-year locoregional recurrence rate of 7...
News
ACE inhibitor prevents trastuzumab-associated LVEF decline after anthracyclines in BC treatment
- Author:
- Neil Osterweil
The rate of left ventricular ejection fraction declines below 50% in patients on anthracyclines and trastuzumab...
News
Pregnancy effect on chemotherapy does not affect maternal breast cancer outcomes
- Author:
- Neil Osterweil
There were no significant differences in survival outcomes between pregnant women with breast cancer and...